BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research AT 2024 GPEN Conference
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia – (July 15, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long […]
A Day To Honour Dr. Daniel Sitar: Fellowship of the Society of Pharmacology and Therapeutics
![dr daniel sitar wide](https://www.biomarkdiagnostics.com/wp-content/uploads/2024/07/dr-daniel-sitar-wide-1024x637.jpg)
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and Therapeutics Daniel Sitar BScPharm, MSc, PhD, FGSA,FCP, Professor Emeritus, Rady Faculty of Health Sciences – College of Medicine (Departments of Internal Medicine, Pharmacology and Therapeutics, Pediatrics and Child Health), College of Pharmacy, and Centre on Aging, University ofManitoba. Dr. Sitar […]
BIOMARK Announces Warrant Extension and Granting of Options
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Company intends to amend […]
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]
BIOMARK PartnerS with RUBIX LS to Advance Blood-based Cancer Screening in Underserved Communities
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic […]
Theresa Peterson Joins BioMark’s Advisory Team
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark’s Advisory team. Mr. Rashid Ahmed Bux, CEO and President of […]
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed […]
insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection
![](https://www.biomarkdiagnostics.com/wp-content/uploads/2024/01/Rashid-A-Bux-CEO-and-Founder-BioMark-Diagnostics-Inc-full.jpg)
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY Vancouver, British Columbia – (December 4th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to […]
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM
![biomark-press-release](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/04/biomark-press-release.jpg)
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British Columbia – (November 28th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results […]